June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Human opticin reduces pathological preretinal neovascularization in the mouse model of oxygen-induced retinopathy.
Author Affiliations & Notes
  • Izabela Paulina Klaska
    Genetics, University College London, Institute of Ophthalmology, London, United Kingdom
  • Catherine Orr
    School of Biological Sciences , University of Manchester, Manchester, United Kingdom
  • Anne White
    School of Biological Sciences , University of Manchester, Manchester, United Kingdom
  • Pilar Villacampa Alcubierre
    Genetics, University College London, Institute of Ophthalmology, London, United Kingdom
  • Laura Abelleira Hervás
    Genetics, University College London, Institute of Ophthalmology, London, United Kingdom
  • Justin Hoke
    Genetics, University College London, Institute of Ophthalmology, London, United Kingdom
  • Catey V Bunce
    King's College London, London, United Kingdom
  • Richard Unwin
    School of Medical Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom
  • Garth Cooper
    School of Medical Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom
  • Paul N Bishop
    School of Biological Sciences , University of Manchester, Manchester, United Kingdom
  • James W B Bainbridge
    Genetics, University College London, Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Izabela Klaska, None; Catherine Orr, None; Anne White, None; Pilar Villacampa Alcubierre, None; Laura Abelleira Hervás, None; Justin Hoke, None; Catey Bunce, None; Richard Unwin, None; Garth Cooper, None; Paul Bishop, Opticin Therapeutics (I), Opticin Therapeutics (P); James Bainbridge, None
  • Footnotes
    Support  MRC DPFS grant (MR/M025365/1)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4063. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Izabela Paulina Klaska, Catherine Orr, Anne White, Pilar Villacampa Alcubierre, Laura Abelleira Hervás, Justin Hoke, Catey V Bunce, Richard Unwin, Garth Cooper, Paul N Bishop, James W B Bainbridge; Human opticin reduces pathological preretinal neovascularization in the mouse model of oxygen-induced retinopathy.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4063.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the therapeutic potential of recombinant human opticin in retinal ischemia and neovascularization.

Methods : Recombinant human opticin was expressed in 293 cells and purified from conditioned media using a three stage chromatography process. To determine the effect of opticin on pathological pre-retinal neovascularisation and retinal vascular regeneration we injected it intravitreally in mice with accelerated oxygen-induced retinopathy at postnatal day 11. We measured the extent of retinal neovascularisation and residual vascular regression at postnatal day 16 by image quantification of fluorescently-labelled vasculature in retinal flat-mounts. The untreated contralateral eye served as an intra-individual control. We compared the effect of opticin with that of PBS and aflibercept.

Results : Intravitreal injection of recombinant human opticin reduced the extent of preretinal neovascularisation by 61%, relative to the untreated contralateral eyes. By comparison, injection of PBS resulted in 42% reduction and aflibercept resulted in 66% reduction.

Conclusions : Local administration of recombinant human opticin reduces pre-retinal neovascularisation in mice and offers the potential for benefit in people with sight impairment owing to retinal ischemia and neovascularization.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×